The Inflation Reduction Act (IRA) contains provisions allowing Medicare to negotiate net prices for prescription drugs, but it remains to be seen whether this will translate into savings for beneficiaries, explained A. Mark Fendrick, MD, co–editor in chief of The American Journal of Managed Care® and director of the V-BID Center at the University of Michigan.
The Inflation Reduction Act (IRA) contains provisions allowing Medicare to negotiate net prices for prescription drugs, but it remains to be seen whether this will translate into savings for beneficiaries, explained A. Mark Fendrick, MD, co–editor in chief of The American Journal of Managed Care® and director of the V-BID Center at the University of Michigan.
Transcript
The IRA includes provisions to lower prescription drug costs in Medicare. How will they impact beneficiaries?
One of the most noteworthy elements of the health care aspects in the Inflation Reduction Act was for the first time giving Medicare the ability to negotiate for prescription drugs. As you know, value-based insurance design focuses more on out-of-pocket costs than total or net cost of drugs. We like to say Americans don't care about health care costs, they care about what it costs them. So the out-of-pocket elements are more important to us at the V-BID Center. But understanding that there is great consternation and a lot of uncertainty regarding how the Medicare negotiations might happen.
It's being phased in over a number of years focusing on some of the most expensive and popular drugs in the beginning. I've read an awful lot about how this actually might work for consumers but also may backfire, in the fact that there are certain ways around this provision and the fact that launch prices may be increased substantially in the first few years to allow those people who do revenue forecasting to make sure that those innovators who make those drugs are able to achieve what they were hoping to make from a financial perspective. But anything that reduces the cost of drugs to patients at the prescription drug counter is very important to us at the V-BID Center. I'm just hopeful that whatever happens regarding the negotiation of the net price of these drugs translates directly into lower out-of-pocket costs for Medicare beneficiaries.
Contributor: Breaking the Cycle—RSAT Program Improving Reentry in Arizona
March 15th 2024Arizona is well suited to benefit from its 1115 demonstration waiver requested from CMS because it already has a robust justice-involved reentry initiative called the Residential Substance Abuse Treatment (RSAT) Program, which is emerging as an archetype of successful reentry programs that can serve as a template for other states to emulate.
Read More
Evolution of HDHPs With VBID Components Can Improve Care for Chronic Disease
March 14th 2024Over the course of the last 20 years, high-deductible health plans (HDHPs) have undergone an evolution. Today’s plans, with more high-value services covered predeductible, can improve care for people with chronic diseases, said panelists at the 2024 Value-Based Insurance Design (V-BID) Summit.
Read More
Fragmented Payer System, Vulnerable Supply Chain Among Threats to Accessing Essential Medicines
March 13th 2024During a session of the 2024 V-BID Summit, panelists Stacie Dusetzina, PhD, and Inma Hernandez, PharmD, PhD, discussed how access to essential medications is curtailed not just by the longstanding complexities of insurance design but also by emerging threats such as supply chain weaknesses and cyberattacks.
Read More